# Leukemias in the Context of Rheumatoid Arthritis: Shared Pathways and Clinical Perspectives

## TL;DR

This paper explores how rheumatoid arthritis increases leukemia risk through shared inflammation and genetic factors, emphasizing the need for close monitoring and interdisciplinary care.

## Contribution

The paper highlights shared pathogenic mechanisms and clinical strategies to address the increased leukemia risk in rheumatoid arthritis patients.

## Key findings

- Chronic inflammation and immune dysregulation in RA contribute to leukemia development.
- Genetic mutations like STAT3, TET2, and DNMT3A are common in both RA and leukemias.
- RA treatments like methotrexate and anti-TNF therapies may influence leukemia risk.

## Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by systemic inflammation, progressive joint destruction, and increased risk of malignancies, particularly hematological cancers such as leukemias. RA patients appear to have a higher incidence of leukemias, suggesting a possible association between the two conditions. This association is driven by shared pathogenic mechanisms, including chronic inflammation, immune dysregulation, and genetic predispositions. Pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), play a crucial role in sustaining an inflammatory microenvironment that promotes leukemic transformation. Genetic alterations, including mutations in STAT3, TET2, and DNMT3A, further highlight the overlap between RA pathophysiology and hematologic malignancies. Moreover, RA treatments such as methotrexate (MTX), Janus kinase (JAK) inhibitors, and anti-TNF therapies have complex implications, with some studies suggesting potential contributions to leukemia risk through immune suppression and hematopoietic alterations. Clinical implications of this association emphasize the necessity of early detection strategies, biomarker-based risk stratification, and close hematologic monitoring in RA patients. Interdisciplinary collaboration between rheumatologists and hematologists is essential for optimizing treatment approaches while minimizing oncogenic risks. Future research should focus on identifying predictive biomarkers, exploring targeted therapeutic interventions, and elucidating the molecular mechanisms underlying RA-associated leukemias. Advances in multiomics and artificial intelligence-driven risk modeling may facilitate personalized treatment strategies, improving both RA management and leukemia prevention. Given the rising burden of RA and its associated complications, a comprehensive understanding of its link to leukemias is critical for enhancing patient outcomes and guiding clinical decision-making.